Lexicon Pharmaceuticals (LXRX) Current Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Current Assets for 17 consecutive years, with $186.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 24.32% year-over-year to $186.0 million; the TTM figure through Mar 2026 stood at $186.0 million (down 24.32% YoY), while the FY2025 annual figure was $101.9 million, down 58.61% from the prior year.
• Current Assets climbed to $186.0 million in Q1 2026 per LXRX's latest filing, from $101.9 million in the prior quarter.
• Across five years, Current Assets topped out at $364.6 million in Q1 2024 and bottomed at $64.9 million in Q2 2022.
• Historically, Current Assets has averaged $188.7 million across 5 years, with a median of $176.5 million in 2023.
• Annual changes were most pronounced in 2023 — Current Assets jumped 306.36% — and 2025, when it slumped 58.61%.
• Lexicon Pharmaceuticals' Current Assets stood at $140.9 million in 2022, then rose by 25.33% to $176.5 million in 2023, then surged by 39.45% to $246.2 million in 2024, then tumbled by 58.61% to $101.9 million in 2025, then jumped by 82.57% to $186.0 million in 2026.
• Business Quant data shows LXRX's Current Assets at $186.0 million in Q1 2026, $101.9 million in Q4 2025, and $122.5 million in Q3 2025.